Pinned · From The Publisher
The Signal · Issue 01 · Coming soon
Why Peptides Are Misunderstood — And Who Benefits From Keeping It That Way
About
Daily Peptide is a publication.
Daily Peptide covers the peptide ecosystem across four lanes. FDA-approved therapeutics. Compounding pharmacy policy. Grey market research chemicals. The supply chain behind all of it.
Peptides are misunderstood. The researchers who study them, the physicians who prescribe them, and the people who use them rarely speak loudly in public. The loudest voices are usually selling something. The result is a space where accurate information is hard to find and easy to fake.
Daily Peptide exists to change that. Evidence-led. Verified. Plainly written. Independent of every commercial interest on every side of the industry.
Editorial Standards
How the publication works.
Evidence First
Every claim is sourced. Mouse data is mouse data. Phase 2 is not Phase 3. Approved for one indication is not approved for all.
Verified Sourcing
Regulatory status, trial data, and FDA actions are verified against primary sources before publishing. The peptide space moves fast. Yesterday's facts are sometimes wrong today.
No Protocols
Daily Peptide does not publish dosing guidance, stacks, or how-to instructions. The publication covers the science, the regulatory landscape, and the industry. It is not a how-to guide.
Plain Language
Complex science made accessible without dumbing it down. No jargon left unexplained. No hype words. No corporate softening.
Independence
Daily Peptide does not accept revenue from any source that could compromise its coverage. When sponsorships exist, they are clearly labeled. No affiliate links. No hidden arrangements. Editorial decisions are made without commercial input.
Coverage
Four lanes. One publication.
FDA Approved
Approved therapeutics and the clinical pipeline.
Coverage of peptides that have completed FDA approval for specific medical indications. Ozempic, Wegovy, Mounjaro, Zepbound, Egrifta, and the late-stage molecules behind them. The publication tracks approvals, ongoing trials, regulatory milestones, and the molecules shaping mainstream medicine.
→
Compounding
How licensed compounding pharmacies work.
Peptides made by licensed pharmacies compounding specifically for individual patients, and by FDA-registered facilities producing at larger scale with federal oversight. Coverage of FDA shortage list changes, enforcement actions, and the rules that determine what compounding pharmacies can legally make.
→
Grey Market
Research chemicals and vendor quality.
Compounds sold as research chemicals, outside the FDA approval framework. Coverage of vendor testing practices, independent lab verification, and supply chain transparency. No vendor endorsements. No rankings tied to revenue.
→
Supply Chain
How peptides actually move.
The infrastructure beneath every lane above. Raw ingredient sourcing, manufacturing facilities, distribution networks, and the economics of how molecules travel from a lab to the person using them. The pipes most readers never see.
→
Why This Exists
Peptides have a place in the future of medicine.
That is not a sales pitch. It is a position the evidence supports and the regulatory landscape is slowly catching up to. The problem is that most people encounter the peptide space through vendor copy, Reddit threads, or sensationalized news coverage. None of those sources are built to get it right.
People deserve accurate information. They deserve to understand what the evidence actually says, what regulators have actually done, and what the real risks and unknowns are. The goal is not to push a position — it is to give readers what they need to form their own.
Daily Peptide is built by someone who cares about getting this right.
Contact
Reach the publication.
General inquiries
hello@dailypeptide.ioSponsorship inquiries
sponsors@dailypeptide.ioPress inquiries
press@dailypeptide.ioReader questions
Ask Daily Peptide →Daily Peptide is an independent peptide research publication. Educational. Not medical advice.